Key Highlights
- Traws Pharma (NASDAQ:TRAW) reported a third-quarter net loss of USD 3.5 million, or USD 0.18 a share, against USD 4.0 million, or USD 0.34 a share, a year earlier.
- Cash and cash equivalents were USD 2.3 million at September 30, 2026, and management says it cannot fund operations for more than one year.
- Research and development expense fell to USD 1.8 million from USD 2.3 million in the quarter, while general and administrative expense was USD 1.8 million.
- The nine-month net loss was USD 14.9 million, against Net Income of USD 16.6 million a year earlier, which included a USD 26.7 million Warrant Fair Value gain.
A Narrower Quarterly Loss Leaves Cash at USD 2.3 Million
Traws Pharma (NASDAQ:TRAW) reported a net loss of USD 3.5 million for the quarter ended September 30, 2026, compared with USD 4.0 million a year earlier. Loss from operations was USD 3.6 million against USD 4.1 million, as Research and Development expense fell to USD 1.8 million from USD 2.3 million. General and administrative expense edged up to USD 1.8 million from USD 1.7 million. The company has no Revenue in the quarter, and its Quarterly Report was filed on November 16, 2026.
Nine-Month Swing Reflects a Prior-Year Warrant Gain
For nine months, the net loss was USD 14.9 million, or USD 0.86 a share, compared with net income of USD 16.6 million, or USD 1.56 a share, a year earlier. The prior-year result included a USD 26.7 million gain from the change in fair value of warrant liabilities, plus USD 2.8 million of revenue. This year, nine-month operating expenses were USD 14.9 million, with research and development at USD 9.0 million and general and administrative at USD 7.3 million, partly offset by USD 1.4 million of other operating income. Net cash used in Operating Activities was USD 12.6 million against USD 15.4 million.
Going Concern Doubt and a USD 10 Million April Financing
Traws Pharma is a clinical stage biopharmaceutical company developing therapies for respiratory viral diseases, formerly known as Onconova Therapeutics. Cash and cash equivalents were USD 2,338,000, and the company says it lacks enough cash to support operations for more than one year, creating substantial doubt about continuing as a going concern. An April 2026 private Placement raised about USD 10.0 million gross, or USD 9.1 million net, and issued warrants, some tied to approval for a human challenge trial in the United Kingdom. The accumulated Deficit was USD 654.8 million. Total liabilities were USD 9.7 million and total Assets USD 7.5 million, while common shares outstanding rose to 15,375,595 from 9,067,774 at year-end. Management plans to explore equity financings, strategic alliances and other funding. The company also revised June 2026 figures for an Australian research and development tax incentive error of USD 1.2 million, which it judged immaterial and which did not affect cash.
Where Things Stand
Traws Pharma (NASDAQ:TRAW) cannot yet fund its trials from existing resources, since USD 2.3 million of cash sits against USD 9.6 million of current liabilities and a Going Concern warning. The quarterly loss narrowed to USD 3.5 million, but that improvement came from lower research spending, not new funding. Nine-month cash burn from operations was USD 12.6 million, so the cash balance covers only a short period at that pace, a calculated inference from the filing. Next markers are new financing, the UK human challenge trial approval and the Series B warrants that depend on trial data.






Please wait processing your request...